Syntegon delivers strong growth and EBITDA improvements in first half of 2025

Oct 6, 2025 | 1 min read

Successful growth strategy delivers sales growth in H1 of +11% versus prior year to €824m
Strong growth momentum in the Pharma segment
EBITDA up +41% to €127m, with margin expanding 300 bps to 15.5%.; all business units contributing
Free cash flow €63m, +11% above 2024’s high benchmark
H1 Book-to-Bill at 117%, signaling strong foundation for future growth
2025 outlook: sustained sales growth and continued margin expansion

Still have questions?

We are happy to help.

Worldwide contacts

Discover more about Syntegon

TEST 2025

DADA

New SynTiso line concept from Syntegon revolutionizes liquid pharmaceutical filling

Joint development with partners from the pharmaceutical industry. The highest output in the market: up to 600 containers per minute. Significantly reduced contamination risk thanks to full automation...

Syntegon reports strong sustainability progress in 2024 and sets ambitious climate targets

2024 sustainability report highlights tangible sustainability gains across emissions, energy, and circularity. Sustainable solutions are a key pillar of the corporate strategy. EcoVadis platinum...